Bristol Myers Squibb and RayzeBio, Inc. recently announced the conclusion of the waiting period as per the HSR Act. This period was connected to Bristol Myers Squibb's pending acquisition of all RayzeBio’s outstanding shares. The offered purchase price for each share was $62.50, approximately totaling to a $4.1 billion deal. The conclusion of this waiting period marks the fulfilment of one of the essential terms required for the completion of the transaction.
The waiting period expired on February 9, 2024, and the offer is set to lapse one minute past 11:59 p.m. New York City time, on February 22, 2024.
